Venezuela (Bolivarian Republic of) Tuberculosis profile

Population 2018 29 million

***
Rate (Rate per 100 000 population per year)
Estimates of TB burdenº, 2018 Number (thousands) (per 100 000 population) 60
Total TB incidence 14 (11–17) 48 (37–60)
HIV-positive TB incidence 1.2 (0.41–2.5) 4.2 (1.4–8.6) 40
MDR/RR-TB incidenceºº 0.4 (0.15–0.77) 1.4 (0.52–2.7)
HIV-negative TB mortality 0.73 (0.69–0.78) 2.5 (2.4–2.7) 20
HIV-positive TB mortality 0.27 (0.088–0.55) 0.94 (0.3–1.9) 0
2000 2004 2008 2012 2016
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 2.1% (0.69–4.3) Total TB incidence
Previously treated cases 14% (9.3–19) New and relapse TB cases notified
HIV-positive TB incidence
TB case notifications, 2018
Total new and relapse 11 017 (Rate per 100 000 population per year)
- % tested with rapid diagnostics at time of diagnosis 4
- % with known HIV status 58% 3
- % pulmonary 87%
- % bacteriologically confirmedººº 76% 2
- % children aged 0-14 years 6%
1
- % women 30%
0
- % men 64%
2000 2004 2008 2012 2016
Total cases notified 11 394
HIV-negative TB mortality
Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)
TB patients facing catastrophic total costs Notified cases by age group and sex, 2018
TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (5–10) 65+
55-64
TB/HIV care in new and relapse TB patients, 2018 Number (%) 45-54
Patients with known HIV status who are HIV-positive 473 7% 35-44
- on antiretroviral therapy 300 63% 25-34
15-24
Drug-resistant TB care, 2018 05-14
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº 0-4
- New cases 6%
2000 1000 0 1000 2000 3000
- Previously treated cases 44%
Laboratory-confirmed cases* MDR/RR-TB: 43, XDR-TB: 0 __ Females __ Males _ Incidence
Patients started on treatment* ** MDR/RR-TB: 41, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs 37 Treatment success rate (%)
100
Treatment success rate and cohort size Success Cohort 80
New and relapse cases registered in 2017 82% 10 647
60
Previously treated cases, excluding relapse, registered in 2017 74% 305
40
HIV-positive TB cases registered in 2017 88% 528
MDR/RR-TB cases started on second-line treatment in 2016 72% 57 20
0
XDR-TB cases started on second-line treatment in 2016 0
2000 2002 2004 2006 2008 2010 2012 2014 2016
TB preventive treatment, 2018 New and relapse
% of HIV-positive people (newly enrolled in care) on preventive treatment 2% Retreatment, excluding relapse
% of children (aged < 5) household contacts of bacteriologically-confirmed 96% (71–100)
HIV-positive MDR/RR-TB XDR-TB
TB cases on preventive treatment

TB financing, 2019 Total budget (US$ millions)

National TB budget (US$ millions) 2.7 3
Funding source: 21% domestic, 0% international, 79% unfunded
2

º Ranges represent uncertainty intervals 1

ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only 0
* Includes cases with unknown previous TB treatment history 2015 2016 2017 2018 2019
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
__ Unfunded
__ Funded internationally
__ Funded domestically

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-11-11 Data: [Link]/tb/data